指南与共识肺血管病与心包/心肌炎

2022 ESC/ERS指南轻度肺动脉高压结局预测因素:EVIDENCE-PAH UK研究

Predictors of outcomes in mild pulmonary hypertension according to 2022 ESC/ERS Guidelines: the EVIDENCE-PAH UK study.
指南 / 共识 · Eur Heart J · 2023-01-01

该研究回顾性分析了英国2009至2017年2929例转诊至PH中心的患者,按mPAP和PVR分层,发现轻度升高的mPAP(21-24 mmHg)或PVR(>2-≤3 WU)患者生存率低于正常压力者,且独立于心肺合并症;68.2%的mPAP 21-24 mmHg患者有潜在心肺疾病。结论支持ESC/ERS指南诊断分类变化,强调严格表型分型以识别进展性血管病患者。

要点

  • 轻度升高的mPAP(21-24 mmHg)或PVR(>2-≤3 WU)与生存率降低独立相关。
  • 大多数新定义类别患者存在潜在心肺疾病,而非孤立性肺血管病。
  • 合并症存在时死亡率更高,需严格表型分型识别进展性血管病风险患者。

核心结论

  • 研究支持ESC/ERS指南对PH诊断分类的修改,新纳入患者死亡率增加且独立于显著心肺疾病。
  • 新类别中多数患者有潜在心肺疾病而非孤立性肺血管病,合并症存在时死亡率更高。

研究设计与样本

  • 回顾性全国性评估,纳入2009至2017年英国PH中心转诊的2929例患者。
  • 按mPAP(<21、21-24、≥25 mmHg)和PVR(≤2、>2-≤3、>3 WU)分层,分别有968例(33.0%)、689例(23.5%)、1272例(43.4%)在mPAP<21、21-24、≥25 mmHg组。

主要发现

  • 整体人群生存率与mPAP和PVR负相关。
  • 68.2%的mPAP 21-24 mmHg患者有潜在心肺疾病证据。
  • 轻度异常血流动力学患者症状并不比正常血流动力学患者更多;排除心肺疾病后,结缔组织病与PH患者生存较差相关;在mPAP 21-24 mmHg亚组中,生存曲线仅在5年后出现分离。

临床怎么用

  • 临床应关注mPAP 21-24 mmHg或PVR>2-≤3 WU的患者,因其死亡风险增加,需评估合并症。
  • 对轻度异常血流动力学患者进行严格表型分型,以识别进展性血管病风险并考虑监测和研究招募。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Interventional studies in pulmonary arterial hypertension completed to date have shown to be effective in symptomatic patients with significantly elevated mean pulmonary artery pressure (mPAP) (≥25 mmHg) and pulmonary vascular resistance (PVR) > 3 Wood Unit (WU). However, in health the mPAP does not exceed 20 mmHg and PVR is 2 WU or lower, at rest. The ESC/ERS guidelines have recently been updated to reflect this. There is limited published data on the nature of these newly defined populations (mPAP 21-24 mmHg and PVR >2-≤3 WU) and the role of comorbidity in determining their natural history. With the change in guidelines, there is a need to understand this population and the impact of the ESC/ERS guidelines in greater detail. METHODS: A retrospective nationwide evaluation of the role of pulmonary haemodynamics and comorbidity in predicting survival among patients referred to the UK pulmonary hypertension (PH) centres between 2009 and 2017. In total, 2929 patients were included in the study. Patients were stratified by mPAP (<21 mmHg, 21-24 mmHg, and ≥25 mmHg) and PVR (≤2 WU, > 2-≤3 WU, and >3 WU), with 968 (33.0%) in the mPAP <21 mmHg group, 689 (23.5%) in the mPAP 21-24 mmHg group, and 1272 (43.4%) in the mPAP ≥25 mmHg group. RESULTS: Survival was negatively correlated with mPAP and PVR in the population as a whole. Survival in patients with mildly elevated mPAP (21-24 mmHg) or PVR (>2-≤3WU) was lower than among those with normal pressures (mPAP <21 mmHg) and normal PVR (PVR ≤ 2WU) independent of comorbid lung and heart disease [hazard ratio (HR) 1.36, 95% confidence interval (CI) 1.14-1.61, P = .0004 for mPAP vs. HR 1.28, 95% CI 1.10-1.49, P = .0012 for PVR]. Among patients with mildly elevated mPAP, a mildly elevated PVR remained an independent predictor of survival when adjusted for comorbid lung and heart disease (HR 1.33, 95% CI 1.01-1.75, P = .042 vs. HR 1.4, 95% CI 1.06-1.86, P = .019). 68.2% of patients with a mPAP 21-24 mmHg had evidence of underlying heart or lung disease. Patients with mildly abnormal haemodynamics were not more symptomatic than patients with normal haemodynamics. Excluding patients with heart and lung disease, connective tissue disease was associated with a poorer survival among those with PH. In this subpopulation evaluating those with a mPAP of 21-24 mmHg, survival curves only diverged after 5 years. CONCLUSIONS: This study supports the change in diagnostic category of the ESC/ERS guidelines in a PH population. The newly included patients have an increased mortality independent of significant lung or heart disease. The majority of patients in this new category have underlying heart or lung disease rather than an isolated pulmonary vasculopathy. Mortality is higher if comorbidity is present. Rigorous phenotyping will be pivotal to determine which patients are at risk of progressive vasculopathic disease and in whom surveillance and recruitment to studies may be of benefit. This study provides an insight into the population defined by the new guidelines.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Karia N, Howard L, Johnson M, et al. Predictors of outcomes in mild pulmonary hypertension according to 2022 ESC/ERS Guidelines: the EVIDENCE-PAH UK study. Eur Heart J. 2023. PMID: 37619574. doi:10.1093/eurheartj/ehad532

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。